The Supreme Court has rejected an attempt to restrict access to the abortion medication mifepristone, ruling that conservative physicians who brought the case lacked standing to challenge the FDA’s approval of the drug. Justice Brett M. Kavanaugh wrote in the opinion that because the plaintiffs do not prescribe, sell or manufacture mifepristone, they suffer no direct financial losses related to FDA regulations.
With this decision, patients and clinicians in the US will continue to have access to mifepristone for medication abortion and miscarriage management. Stella Dantas, president of the American College of Obstetricians and Gynecologists, stated that decades of research have shown mifepristone to be safe and effective, with millions of patient uses confirming its positive track record.
The Supreme Court’s ruling is a victory for reproductive rights and access to safe and effective medical care. The case underscores the importance of evidence-based practices and regulatory bodies in ensuring patients have access to vital medications.
